-$0.21 Earnings Per Share Expected for Infinity Pharmaceuticals, Inc. (INFI) This Quarter
Wall Street analysts expect that Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will announce earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Infinity Pharmaceuticals’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.22). Infinity Pharmaceuticals posted earnings of ($0.39) per share in the same quarter last year, which suggests a positive year over year growth rate of 46.2%. The business is scheduled to announce its next earnings report on Wednesday, November 8th.
According to Zacks, analysts expect that Infinity Pharmaceuticals will report full-year earnings of ($0.94) per share for the current fiscal year, with EPS estimates ranging from ($0.98) to ($0.86). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.60) per share, with EPS estimates ranging from ($2.94) to ($0.91). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Infinity Pharmaceuticals.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by $0.12. During the same period last year, the firm posted $1.05 earnings per share.
Several brokerages recently commented on INFI. ValuEngine raised shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. Zacks Investment Research downgraded shares of Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 16th.
Shares of Infinity Pharmaceuticals (NASDAQ:INFI) traded down 1.80% during mid-day trading on Thursday, hitting $1.09. The company had a trading volume of 223,673 shares. The firm’s 50-day moving average price is $1.38 and its 200 day moving average price is $2.07. The company’s market capitalization is $55.25 million. Infinity Pharmaceuticals has a one year low of $0.84 and a one year high of $3.84.
WARNING: “-$0.21 Earnings Per Share Expected for Infinity Pharmaceuticals, Inc. (INFI) This Quarter” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/17/0-21-earnings-per-share-expected-for-infinity-pharmaceuticals-inc-infi-this-quarter.html.
Several institutional investors have recently added to or reduced their stakes in INFI. Vanguard Group Inc. increased its position in Infinity Pharmaceuticals by 27.7% in the first quarter. Vanguard Group Inc. now owns 4,701,769 shares of the biotechnology company’s stock valued at $15,187,000 after buying an additional 1,021,128 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Infinity Pharmaceuticals by 689.0% in the first quarter. Acadian Asset Management LLC now owns 585,232 shares of the biotechnology company’s stock worth $1,888,000 after buying an additional 511,057 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of Infinity Pharmaceuticals during the first quarter worth $1,588,000. Legal & General Group Plc increased its position in shares of Infinity Pharmaceuticals by 2,430.0% in the second quarter. Legal & General Group Plc now owns 349,346 shares of the biotechnology company’s stock worth $548,000 after buying an additional 335,538 shares in the last quarter. Finally, Platinum Investment Management Ltd. increased its position in shares of Infinity Pharmaceuticals by 62.6% in the first quarter. Platinum Investment Management Ltd. now owns 810,232 shares of the biotechnology company’s stock worth $2,617,000 after buying an additional 312,000 shares in the last quarter. 75.16% of the stock is owned by hedge funds and other institutional investors.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.